Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study

Serum IgG antibodies to Shigella lipopolysaccharide antigens – a correlate of protection against shigellosis

(2019) Dani Cohen et al.   Human Vaccines & Immunotherapeutics

Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human

(2019) Louis-Antoine Barel et al.   Human Vaccines & Immunotherapeutics

Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016

(2018) Ibrahim A Khalil et al.   LANCET INFECTIOUS DISEASES

Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study

(2018) Elizabeth T Rogawski et al.   Lancet Global Health

A Synthetic Carbohydrate Conjugate Vaccine Candidate against Shigellosis: Improved Bioconjugation and Impact of Alum on Immunogenicity

(2016) Robert M. F. van der Put et al.   BIOCONJUGATE CHEMISTRY

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study

(2016) Mark S. Riddle et al.   Clinical and Vaccine Immunology

Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study

(2016) Avital A. Shimanovich et al.   Clinical and Vaccine Immunology

Association Between Shigella Infection and Diarrhea Varies Based on Location and Age of Children

(2015) Brianna Lindsay et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development

(2014) S. Livio et al.   CLINICAL INFECTIOUS DISEASES

Recent trends in the epidemiology of shigellosis in Israel

(2014) D. COHEN et al.   EPIDEMIOLOGY AND INFECTION

Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a

(2013) Rezwanul Wahid et al.   CLINICAL IMMUNOLOGY

Shigella flexneriO-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity

(2012) Andrei V. Perepelov et al.   FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY

Dynamic aspects of antibody:oligosaccharide complexes characterized by molecular dynamics simulations and saturation transfer difference nuclear magnetic resonance

(2011) François-Xavier Theillet et al.   GLYCOBIOLOGY

Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1–4-year-old Israeli children

(2010) Justen H. Passwell et al.   VACCINE

A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Shigella flexneri 2a Infection

(2009) A. Phalipon et al.   JOURNAL OF IMMUNOLOGY

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody

(2008) B. Vulliez-Le Normand et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA